tiprankstipranks
Trending News
More News >
Jubilant Pharmova Limited (IN:JUBLPHARMA)
:JUBLPHARMA
India Market
Advertisement

Jubilant Pharmova Limited (JUBLPHARMA) Price & Analysis

Compare
1 Followers

JUBLPHARMA Stock Chart & Stats


Jubilant Pharmova Limited News

JUBLPHARMA FAQ

What was Jubilant Pharmova Limited’s price range in the past 12 months?
Jubilant Pharmova Limited lowest stock price was ₹823.70 and its highest was ₹1309.00 in the past 12 months.
    What is Jubilant Pharmova Limited’s market cap?
    Jubilant Pharmova Limited’s market cap is ₹178.04B.
      When is Jubilant Pharmova Limited’s upcoming earnings report date?
      Jubilant Pharmova Limited’s upcoming earnings report date is Oct 17, 2025 which is in 70 days.
        How were Jubilant Pharmova Limited’s earnings last quarter?
        Jubilant Pharmova Limited released its earnings results on Jul 29, 2025. The company reported ₹6.5 earnings per share for the quarter, beating the consensus estimate of ₹6.4 by ₹0.1.
          Is Jubilant Pharmova Limited overvalued?
          According to Wall Street analysts Jubilant Pharmova Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Jubilant Pharmova Limited pay dividends?
            Jubilant Pharmova Limited pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.45%. See more information on Jubilant Pharmova Limited dividends here
              What is Jubilant Pharmova Limited’s EPS estimate?
              Jubilant Pharmova Limited’s EPS estimate is 6.6.
                How many shares outstanding does Jubilant Pharmova Limited have?
                Jubilant Pharmova Limited has 159,281,140 shares outstanding.
                  What happened to Jubilant Pharmova Limited’s price movement after its last earnings report?
                  Jubilant Pharmova Limited reported an EPS of ₹6.5 in its last earnings report, beating expectations of ₹6.4. Following the earnings report the stock price went down -1.644%.
                    Which hedge fund is a major shareholder of Jubilant Pharmova Limited?
                    Currently, no hedge funds are holding shares in IN:JUBLPHARMA

                    Company Description

                    Jubilant Pharmova Limited

                    Jubilant Pharmova Limited is a prominent player in the global pharmaceutical industry, headquartered in India. The company operates across multiple segments including Pharmaceuticals, Life Science Ingredients, and Drug Discovery & Development Solutions. Jubilant is dedicated to providing high-quality pharmaceutical products and services, leveraging its expansive portfolio that spans generics, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The company's commitment to innovation and quality has positioned it as a trusted partner in the healthcare sector worldwide.

                    Jubilant Pharmova Limited (JUBLPHARMA) Earnings & Revenues

                    JUBLPHARMA Stock 12 Month Forecast

                    Average Price Target

                    ₹1,385.00
                    ▲(23.91% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"857":"₹857","1386":"₹1,386","989.25":"₹989.3","1121.5":"₹1,121.5","1253.75":"₹1,253.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.39K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.39K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.39K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[857,989.25,1121.5,1253.75,1386],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1192.5,1207.3076923076924,1222.1153846153845,1236.923076923077,1251.7307692307693,1266.5384615384614,1281.3461538461538,1296.1538461538462,1310.9615384615386,1325.7692307692307,1340.576923076923,1355.3846153846155,1370.1923076923076,{"y":1385,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1192.5,1207.3076923076924,1222.1153846153845,1236.923076923077,1251.7307692307693,1266.5384615384614,1281.3461538461538,1296.1538461538462,1310.9615384615386,1325.7692307692307,1340.576923076923,1355.3846153846155,1370.1923076923076,{"y":1385,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1192.5,1207.3076923076924,1222.1153846153845,1236.923076923077,1251.7307692307693,1266.5384615384614,1281.3461538461538,1296.1538461538462,1310.9615384615386,1325.7692307692307,1340.576923076923,1355.3846153846155,1370.1923076923076,{"y":1385,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":858.03,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":904.73,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1162.58,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1207.19,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1198.23,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1076,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":968.41,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":898.61,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":910.51,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":893.48,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1164.62,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1164.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1192.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Alembic Pharmaceuticals Limited
                    Caplin Point Laboratories Limited
                    Granules India Limited
                    NATCO Pharma Limited
                    Neuland Laboratories Ltd.
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis